Effects of gender-affirming hormone therapy on lower urinary tract symptoms and sexual function among transgender individuals.
gender‐affirming hormone therapy
lower urinary tract symptoms
sexual dysfunction
transgender
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
revised:
24
09
2024
received:
26
04
2024
accepted:
30
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
aheadofprint
Résumé
Gender-affirming hormone therapy (GAHT) includes estrogen preparations and androgen inhibitors for transgender women, and testosterone preparations for transgender men. The aim of the study was to investigate possible effects of GAHT on lower urinary tract symptoms (LUTS) and sexual function among transgender individuals. Fifty-one transgender men and 47 transgender women were prospectively recruited. Four validated female questionnaires (Bristol Female Lower Urinary Tract Symptoms [BFLUTS] questionnaire, the Medical, Epidemiologic, and Social aspects of Aging [MESA] questionnaire, Urgency, the Severity and Impact Questionnaire [USIQ], and the Female Sexual Function Index [FSFI]) and two validated male questionnaires (International Prostate Symptom Score [IPSS], and the International Index of Erectile Function [IIEF]) were used to assess LUTS and sexual function among transgender men and women, respectively, before and during GAHT. Follow-up was performed over a period of 3-12 months. Thirty-four transgender men (mean age 24.4 ± 7.6 years) and 31 transgender women (mean age 29 ± 8.7 years) completed all questionnaires, before and during GAHT. Testosterone treatment was associated with a statistically significant improvement in sexual desire among transgender men, as reflected in the FSFI questionnaire (4.5 ± 1.2 vs. 3.6 ± 1.3, P = 0.002). None of the three LUTS questionnaires showed statistically significant changes during the treatment with testosterone preparations. Estrogen treatment was associated with a statistically significant decrease in erectile function among transgender women, as reflected by the IIEF questionnaire (9.0 ± 7.2 vs. 14.1 ± 11.1, P = 0.012). No significant changes were found in LUTS during the treatment with estrogen preparations, except for a slight worsening of nocturia (2.1 ± 1.8 vs. 1.1 ± 1.4, P = 0.009). GAHT was not found to be associated with significant LUTS in both transgender men and women. Nevertheless, some effects on sexual function were observed, mainly a decrease in erectile function among transgender women and an increase in sexual desire among transgender men.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
Références
T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev. 2019;40(1):97‐117. doi:10.1210/er.2018-00011
Schulster M, Bernie AM, Ramasamy R. The role of estradiol in male reproductive function. Asian J Androl. 2016;18(3):435‐440. doi:10.4103/1008-682X.173932
Wåhlin‐Jacobsen S, Pedersen AT, Kristensen E, et al. Is there a correlation between androgens and sexual desire in women? J Sex Med. 2015;12(2):358‐373. doi:10.1111/jsm.12774
Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol. 2011;185(1):17‐23. doi:10.1016/j.juro.2010.08.094
Mancini A, Milardi D, Bianchi A, Summaria V, De Marinis L. Increased estradiol levels in venous occlusive disorder: a possible functional mechanism of venous leakage. Int J Impot Res. 2005;17(3):239‐242. doi:10.1038/sj.ijir.3901287
Kim MM, Kreydin EI. The association of serum testosterone levels and urinary incontinence in women. J Urol. 2018;199(2):522‐527. doi:10.1016/j.juro.2017.08.093
Berman JR, Almeida FG, Jolin J, Raz S, Chaudhuri G, Gonzalez‐Cadavid NF. Correlation of androgen receptors, aromatase, and 5‐alpha reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925‐931. doi:10.1016/s0015-0282(02)04923-3
Townsend MK, Danforth KN, Lifford KL, et al. Incidence and remission of urinary incontinence in middle‐aged women. Am J Obstet Gynecol. 2007;197(2):167. e1‐167. e1675. doi:10.1016/j.ajog.2007.03.041
Cheung CP, Yu S, Wong KB, et al. Expression and functional study of estrogen receptor‐related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab. 2005;90(3):1830‐1844. doi:10.1210/jc.2004-1421
Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009;12(2):160‐165. doi:10.1038/pcan.2008.50
Nicholson TM, Ricke EA, Marker PC, et al. Testosterone and 17β‐estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. Endocrinology. 2012;153(11):5556‐5565. doi:10.1210/en.2012-1522
Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgender Health. 2022;23(Suppl 1):S1‐S259. doi:10.1080/26895269.2022.2100644
Brookes ST, Donovan JL, Wright M, Jackson S, Abrams P. A scored form of the Bristol female lower urinary tract symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol. 2004;191(1):73‐82. doi:10.1016/j.ajog.2003.12.027
Diokno AC, Brock BM, Brown MB, Herzog AR. Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. J Urol. 1986;136(5):1022‐1025.
Lowenstein L, FitzGerald MP, Kenton K, et al. Evaluation of urgency in women, with a validated urgency, severity and impact questionnaire (USIQ). Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(3):301‐307. doi:10.1007/s00192-008-0770-0
Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self‐report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191‐208. doi:10.1080/009262300278597
Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549‐1557. doi:10.1016/s0022-5347(17)36966-5
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822‐830. doi:10.1016/s0090-4295(97)00238-0
Schatzl G, Brössner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The prostate study Group of the Austrian Society of urology. Urology. 2000;55(3):397‐402. doi:10.1016/s0090-4295(99)00473-2
Alvarado M, Cuevas E, Lara‐García M, et al. Effect of gonadal hormones on the cross‐sectional area of pubococcygeus muscle fibers in male rat. Anat Rec (Hoboken). 2008;291(5):586‐592. doi:10.1002/ar.20694
Celayir S. Effects of different sex hormones on male rabbit urodynamics: an experimental study. Horm Res. 2003;60(5):215‐220. doi:10.1159/000074034
Kerckhof ME, Kreukels BPC, Nieder TO, et al. Prevalence of sexual dysfunctions in transgender persons: results from the ENIGI follow‐up study. J Sex Med. 2019;16(12):2018‐2029. doi:10.1016/j.jsxm.2019.09.003
Defreyne J, Elaut E, Kreukels B, et al. Sexual desire changes in transgender individuals upon initiation of hormone treatment: results from the longitudinal European network for the investigation of gender incongruence. J Sex Med. 2020;17(4):812‐825. doi:10.1016/j.jsxm.2019.12.020
Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta‐analysis. Fertil Steril. 2017;107(2):475‐482.e15. doi:10.1016/j.fertnstert.2016.10.028